Work

Baseline characteristics of patients enrolled in the FIBRONEER-ILD trial of nerandomilast (BI 1015550)

Year: 2024

Type: conference-abstract

DOI: 10.1183/13993003.congress-2024.pa671

Authors: Toby M Maher, Shervin Assassi, Arata Azuma, Vincent Cottin, Anna-Maria Hoffmann-Vold, Michael Kreuter, Justin M. Oldham, Luca Richeldi, Claudia Valenzuela, Marlies S. Wijsenbeek, Carl Coeck, Arno Schlosser, Daniel Wachtlin, Fernando J. Martinez

Institutions: University of Southern California, Nippon Medical School, Lyon 1 Université, Hospices Civils de Lyon, Hôpital Louis Pradel, Oslo University Hospital, University Medical Center of the Johannes Gutenberg University Mainz, University of Michigan, Michigan Medicine, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Erasmus MC, Boehringer Ingelheim (Belgium), Boehringer Ingelheim (Germany), NewYork–Presbyterian Hospital

Language: English

Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4404103335

Cites:

Cited by:

Related to: 10